Yes. A PSEN1 genetic test can confirm or rule out an inherited cause of early-onset Alzheimer's disease, which directly changes how a second-opinion team approaches diagnosis, family risk counseling, and treatment options.
PSEN1 is the gene most often responsible for early-onset familial Alzheimer's disease, accounting for an estimated 20 to 70 percent of such cases depending on the population studied, which makes it the primary genetic target when a dementia work-up considers an inherited cause, according to Lab Tests Online UK. A positive or negative PSEN1 result gives a second-opinion neurologist or memory clinic team concrete information that a clinical picture alone cannot provide. It can confirm a diagnosis, open access to specialized trials, and tell family members their own risk — each of which shapes a different set of next steps.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- When Does PSEN1 Testing Actually Apply?
- What a Positive Result Changes About Diagnosis and Care
- Why Families Seek a Second Opinion Before Testing
- What Testing Means for Family Members Who Have No Symptoms
- How to Bring PSEN1 Testing Into a Second-Opinion Visit
- Frequently Asked Questions
When Does PSEN1 Testing Actually Apply?
PSEN1 testing is not a general dementia screening tool. It is intended for people who develop dementia symptoms early, combined with a strong family history — ideally three affected generations — or for unaffected relatives of someone already confirmed to carry the mutation, according to Lab Tests Online UK. It is not meant for population screening or for the far more common late-onset form of Alzheimer's disease that appears after age 65. This distinction matters when a reader is deciding whether to ask a second-opinion team about genetic testing.
A person in their 70s with no family history of early dementia is not the typical candidate. A person who developed memory or behavioral symptoms in their 40s or 50s, especially with parents or siblings affected at similarly young ages, fits the profile testing was designed for. Among the genes linked to dominantly inherited Alzheimer's disease, PSEN1 carriers tend to show the youngest and most aggressive onset, often developing symptoms before age 45, based on a summary of the DIAN cohort analysis reported by Omnicuris. That early, aggressive pattern is often what prompts a family to seek a second opinion in the first place, and it is also what prompts a second-opinion team to pursue genetic confirmation more urgently than they might for an older patient.
What a Positive Result Changes About Diagnosis and Care
A clinical laboratory report identifying a pathogenic PSEN1 variant states that the finding is consistent with early-onset Alzheimer's disease, and it recommends the patient pursue genetic counseling and a neurological consultation to act on the result, based on a sample report from ARUP Laboratories. In practice, that means a second-opinion team moving from a suspected diagnosis to a confirmed genetic cause, which narrows the differential and can end a diagnostic search that had been running in circles. Confirmation also reframes the conversation with family members. Because PSEN1 follows an autosomal dominant inheritance pattern, each child of a confirmed carrier has a 50 percent chance of inheriting the mutation, and genetic counseling before testing is considered essential for both the symptomatic patient and at-risk relatives, given that disease course can vary even within the same family, according to a case report in the Hong Kong Medical Journal.
A second opinion that includes genetic testing is often as much about informing relatives as it is about the original patient. A confirmed mutation can also open a door that a clinical diagnosis alone cannot: eligibility for prevention trials. A confirmed PSEN1, APP, or PSEN2 mutation is a documented eligibility requirement for the Dominantly Inherited Alzheimer Network Trial, known as DIAN-TU, according to the trial protocol listed on ClinicalTrials.gov. For a family already searching for options beyond standard care, that access can be the single most consequential outcome of testing.
Why Families Seek a Second Opinion Before Testing
Diagnostic uncertainty, disagreement between prior providers, and atypical or fluctuating symptoms are common, legitimate reasons to seek a second dementia opinion, typically through a memory clinic team made up of geriatricians, neurologists, geriatric psychiatrists, and neuropsychologists, according to AlzInfo.org, published by the Fisher Center for Alzheimer's Research Foundation. A young patient with a confusing or inconsistent symptom pattern is exactly the kind of case where a second opinion — and a closer look at family history — tends to surface the possibility of a genetic cause that a first evaluation missed.
A second opinion does not require a genetic red flag to be appropriate. In the UK, the Royal College of Psychiatrists recommends specialist referral for dementia diagnosis whenever a case is complex or uncertain, or simply when the patient or family requests one, independent of any genetic finding, according to referral guidance summarized by GPnotebook. PSEN1 testing becomes relevant once that second-opinion team identifies the early-onset, family-history pattern that makes a genetic cause plausible.
What Testing Means for Family Members Who Have No Symptoms
A positive result in one family member raises the question of whether unaffected relatives should be tested too. The Alzheimer's Association advises against genetic risk testing of asymptomatic healthy individuals until they first receive genetic counseling, and it states that such tests currently hold their greatest value in research studies or clinical trials rather than in routine care decisions, according to the Alzheimer's Association Genetic Testing Statement. This is why a second-opinion referral for a symptomatic patient often comes paired with a referral to a genetic counselor for the rest of the family, rather than a blanket recommendation to test everyone.
Real-world experience with presymptomatic testing supports the counseling-first approach rather than discouraging testing outright. In a Spanish program called PiCOGEN, 24 of 54 asymptomatic at-risk relatives chose to undergo PSEN1 or APP testing after individual genetic counseling, and 10 of those 24 — 42 percent — were confirmed carriers, with no major psychiatric complication reported during follow-up, according to the program's report in Neurología (English edition). That outcome suggests relatives can process a carrier result without the testing process itself causing harm, provided counseling comes first.
How to Bring PSEN1 Testing Into a Second-Opinion Visit
A reader weighing whether to raise genetic testing with a second-opinion team can prepare for that conversation with a few concrete steps: A second opinion that includes this groundwork turns a genetic test from a standalone lab result into a decision point the whole care team and family can act on together.
- Document the family history in detail — who was affected, at what age symptoms started, and how the disease progressed in each relative.
- Ask the second-opinion team whether the patient's age at onset and family pattern meet the threshold where PSEN1 testing is typically considered.
- Request a referral to a genetic counselor before any blood is drawn, for both the patient and any relative considering testing.
- Ask what a positive result would change about treatment, including whether it would open eligibility for trials such as DIAN-TU.
- Ask what a negative result would mean, since a negative PSEN1 result does not rule out other genetic or non-genetic causes of early-onset dementia.
Frequently Asked Questions
Does a negative PSEN1 result rule out early-onset Alzheimer's disease?
No. PSEN1 is the most common cause of early-onset familial Alzheimer's, but other genes and non-genetic causes can still produce the same symptoms, so a negative result narrows rather than eliminates the possibilities a second-opinion team considers.
Can a family member get tested without the affected relative being tested first?
Testing an at-risk relative is most informative once a family mutation has been confirmed, and the Alzheimer's Association advises genetic counseling before any asymptomatic person proceeds, per the Alzheimer's Association Genetic Testing Statement.
Does a confirmed PSEN1 mutation guarantee access to a clinical trial?
It satisfies one documented eligibility requirement for trials like DIAN-TU, according to the DIAN-TU-001 protocol, but each trial still applies its own additional criteria.
